Home › Alzheimer's Disease › NCT05904132

Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

Who can join

Ages 50 to 80 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Overall cognitive functional status consistent with amnesic MCI (CDR 0.5) likely due to AD (AD biomarker supported)
* 50-80 years of age
* English native speakers

Exclusion Criteria:

* Known presence of a structural brain lesion (e.g., tumor, cortical infarct)
* Acute or decompensated active medical conditions, including cancer, cardiovascular disease, stroke, congestive heart failure
* Active hematological, renal, pulmonary, endocrine or hepatic disorders
* Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
* tACS contraindications (lesions in the scalp, history of seizures)

About the study

The project is a placebo-controlled study that aims to use closed-loop transcranial alternating current stimulation (tACS) to study patients with symptoms of mild cognitive impairment which is likely due to Alzheimer's disease or another form of dementia (AD-MCI). Patients will undergo an EEG and complete some questionnaires and computer tasks during each study visit. The project has the following aims and hypotheses: 1.) To determine the impact of closed-loop 40 Hz tACS on the entrainment of natural gamma rhythms in patients with AD-MCI, 2.) To determine the impact of closed-loop 40 Hz tACS on cognitive performance in patients with AD-MCI, and 3.) To assess the relationship between baseline neurodegenerative burden and impact of tACS. \[exploratory\]

What is being tested

• tACS device (device)

Sponsor: Massachusetts General Hospital · Participants: 70 · Started: Jan 31, 2025

Contact the study team

• DNN Inbox · Phone: 6177265348

Official record on ClinicalTrials.gov — NCT05904132

Locations in the U.S.

Conditions

• Alzheimer's Disease
• Mild Cognitive Impairment

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.